Three coronary stent models from Meril Life Sciences were withdrawn from the Sri Lankan market due to performance issues. The National Medicines Regulatory Authority conducted an investigation that revealed critical failures. The Central Drugs Standard Control Organisation is auditing manufacturing facilities to address quality concerns. Stricter regulations and robust post-market surveillance measures are necessary to ensure patient safety.